EUVIMEDEUVIMED entdecken
Crossref

Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia

Lei Ye, Zhenzhen Cui, Yu Sun, Haikun Zhou, Quanjin Rong, Dan Wang, Jiaming Jin, Qijian Zhang, Di Kang, Lihong Hu, Junwei Wang

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Lei Ye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR C…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Antineoplastic Agents, Pyrazines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fms-like tyrosine receptor kinase 3 (FLT3) proteolysis targeting chimeras (PROTACs) emerge as a promising approach to overcome the limitations of FLT3 inhibitors, while the development of orally bioavailable FLT3-PROTACs faces great challenges. Here, we report the rational design and evaluation of a series of Gilteritinib-based FLT3-PROTACs. Among them, B3-2 exhibited the strongest antiproliferative activity against FLT3-ITD mutant AML cells, and significantly induced FLT3-ITD protein degradation. Mechanistic investigations demonstrated that B3-2 induced FLT3-ITD degradation in a ubiquitin-proteasome-dependent manner. More importantly, B3-2 exhibited an oral bioavailability of 5.65%, and oral administration of B3-2 showed good antitumor activity in MV-4-11 xenograft models. Furthermore, B3-2 showed strong antiproliferative activity against FLT3 resistant mutations, highlighting its potential in overcoming drug resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteAntineoplastic AgentsPyrazinesCell ProliferationProtein Kinase InhibitorsDrug Screening Assays, AntitumorDose-Response Relationship, DrugHumansAnimalsStructure-Activity RelationshipMolecular StructureMiceDrug DiscoveryThiophenesProteolysisAniline CompoundsCell Line, TumorNeoplasms, Experimental

Stichwörter der Autor:innen

Acute myeloid leukemiaDegraderDrug resistanceFLT3-ITDProteolysis targeting chimera

Substanzen

fms-Like Tyrosine Kinase 3gilteritinibFLT3 protein, humanAntineoplastic AgentsPyrazinesProtein Kinase InhibitorsThiophenesAniline Compounds

Autor:innen und Institutionen

  • Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
  • Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China; National Key Laboratory on Technologies for Chinese Medicine Pha…

Zitieren

APA

Ye, L., Cui, Z., Sun, Y., Zhou, H., Rong, Q., Wang, D., Jin, J., Zhang, Q., Kang, D., Hu, L., & Wang, J. (2024). Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107477

Vancouver

Ye L, Cui Z, Sun Y, Zhou H, Rong Q, Wang D, et al. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107477

BibTeX
@article{Ye2024,
  author = {Ye, Lei and Cui, Zhenzhen and Sun, Yu and Zhou, Haikun and Rong, Quanjin and Wang, Dan and Jin, Jiaming and Zhang, Qijian and Kang, Di and Hu, Lihong and Wang, Junwei},
  title = {Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107477}
}
Kostenlos starten →